StocksInsys Therapeutics IncINSY

INSY

Insys Therapeutics Inc

0.0420 0 (0%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
0.3000
B
0.3100

Overview

Prev Close0.0420
Day's Range0.3000 - 0.3000
52 Week Range -
Average Volume (3m)201.28K
1-Year Return0%
Beta2.6982
Market Cap3.13M
P/E Ratio
Revenue65.8M
EPS-3.0676
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Chart times in UTC
Industry Biotechnology
CEO Andrew G. Long, MBA
Employees 226

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2018: Insys Therapeutics Inc's revenues decreased by 41.66% and amounted to 82.08M. Net income increased by 45.40% to -124.51M. Net assets decreased by NaN to N/A and EPS increased from -3.16 to -1.68.
INSY's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
79.98%
Net Profit Margin
-73.05%
Operating Margin
-212.12%
Return On Investment
-6.95%
06/18
09/18
12/18
03/19
Total Revenue
23.47M
18.35M
16.36M
7.63M
Gross Profit
19.87M
15.97M
13.73M
3.06M
Operating Income
-27.71M
-30.79M
-32.96M
-48.12M
Net Income
-27.35M
-30.58M
-46.29M
-123.84M